Plain-English Summary
STEP 1 is the flagship obesity trial showing that weekly semaglutide 2.4 mg produced large average weight loss over 68 weeks in adults without diabetes when paired with lifestyle intervention.
VV Study Evidence Matrix v1.0
VV Evidence Utility Score
A bounded score for how useful this study is in public explanation, based on evidence tier, design, applicability, endpoint relevance, limitations, safety signals, and publication/source strength.
81/100
Useful Public Evidence
- Evidence tier
- 92/100, weight 18%
- Design strength
- 100/100, weight 18%
- Applicability
- 75/100, weight 16%
- Endpoint relevance
- 68/100, weight 16%
- Limitations transparency
- 70/100, weight 12%
- Safety signal usefulness
- 57/100, weight 10%
- Publication/source strength
- 90/100, weight 10%
Useful for context, but limited by safety signal usefulness, endpoint relevance, limitations transparency.
How the study framework works ->Key Findings
- Mean body weight changed by -14.9% with semaglutide versus -2.4% with placebo at week 68.
- A much larger share of participants reached clinically meaningful weight-loss thresholds with semaglutide, including at least 5% body-weight loss.
- Cardiometabolic risk markers, including waist circumference and blood pressure, generally moved more favorably with semaglutide than placebo.
- Gastrointestinal adverse events were common and were more frequent with semaglutide than placebo.
Limitations
- The trial excluded people with diabetes, so the findings should not be generalized to all metabolic-disease populations.
- Controlled trial conditions, lifestyle counseling, and follow-up intensity differ from broad real-world use.
- The trial shows strong 68-week efficacy, but does not answer indefinite treatment, discontinuation, affordability, or long-term adherence questions.
Why It Matters
This is one of the core studies behind semaglutide's weight-management story, but it should be read as a treated-trial-population result rather than a promise of effortless or permanent weight loss for every user.
Viral Vitalism Verdict
High-value human evidence for obesity treatment efficacy, with the usual GLP-1 caveats: side effects, adherence, cost, discontinuation, and patient selection still matter.
Sources
- Once-weekly semaglutide in adults with overweight or obesity - New England Journal of Medicine
- STEP 1 semaglutide obesity trial - PubMed
Signal cards
Used in signals
Signal coverage connected to this study through explicit study links, canonical source refs, or evidence visualizations.
GLP-1s Are Not Just a Weight Loss Story
GLP-1 medications are being studied for effects that may extend beyond weight loss, including cardiometabolic outcomes and behavior-related pathways.
VV Signal Score
76
Promising signal
- Sources
- 31
- Studies
- 11
- Claims
- 16
Claim ledger
Relevant claims
Claim ledger records connected through this study's ID, topic tags, or source IDs.
semaglutide: Semaglutide reduced body weight in adults with obesity or
Semaglutide reduced body weight in adults with obesity or overweight in randomized clinical-trial populations.
glp 1: Semaglutide and tirzepatide produce clinically meaningful average weight loss
Semaglutide and tirzepatide produce clinically meaningful average weight loss in studied adults with obesity or overweight, with results and tolerability varying by drug, dose, and patient context.
glp 1: Semaglutide and tirzepatide should not be collapsed into one
Semaglutide and tirzepatide should not be collapsed into one generic claim because their mechanisms, labels, trial programs, and outcome evidence differ.
glp 1: Public GLP-1 claims are distorted by both promotional hype
Public GLP-1 claims are distorted by both promotional hype and categorical backlash, neither of which substitutes for indication-specific evidence.
glp 1: FDA-approved GLP-1 products and compounded, unapproved, or falsely labeled
FDA-approved GLP-1 products and compounded, unapproved, or falsely labeled products are different regulatory and quality-risk categories.
glp 1: GLP-1 therapies have meaningful gastrointestinal adverse effects and label-level
GLP-1 therapies have meaningful gastrointestinal adverse effects and label-level tolerability considerations.